Roche inks $308.6M col­lab­o­ra­tion deal with Lead Phar­ma, fo­cus­ing on im­mune-me­di­at­ed dis­ease

Roche is wad­ing deep­er in­to the field of im­mune-me­di­at­ed dis­ease with a €260 mil­lion ($308.6 mil­lion) col­lab­o­ra­tion deal with Nether­lands-based biotech Lead Phar­ma.

The gi­ant phar­ma is putting down €10 mil­lion ($11.8 mil­lion) up­front to work with Lead over the next few years on re­search­ing a small mol­e­cule can­di­date that in­hibits por­tions of the T helper 17 (TH17) cell path­way, which could treat a va­ri­ety of au­toim­mune dis­eases. Once a pre­clin­i­cal can­di­date is cho­sen, it’ll be up to Roche to de­vel­op and com­mer­cial­ize it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Principal

Alexandria Real Estate Equities

Cambridge, MA, USA